A Study of GC203 TIL in PDCA (RJ)

Summary

This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Timeline

Start

2025-02-10

Primary completion

2028-01-31

Completion

2028-01-31

Drugs

Indications